25 research outputs found
Levantamento de plantas medicinais cultivadas no municĂpio de SolĂąnea, agreste paraibano: reconhecimento e valorização do saber tradicional
RESUMO Objetivou-se neste trabalho reconhecer e sistematizar o conhecimento tradicional sobre as espĂ©cies medicinais, as indicaçÔes terapĂȘuticas, as formas de uso e as tĂ©cnicas de produção e comercialização de plantas medicinais no agreste nordestino, no municĂpio de SolĂąnea, ParaĂba. Visitas, entrevistas e amostragem foram realizadas a agricultores familiares da regiĂŁo por meio de entrevistas semiestruturadas utilizando a tĂ©cnica de turnĂȘ guiada. ApĂłs as visitas foi identificada uma atriz - informante. Foi feito um herbĂĄrio com as plantas medicinais encontradas, nas quais foram identificadas e categorizadas quanto Ă s indicaçÔes terapĂȘuticas de acordo com a Classificação EstatĂstica Internacional de Doenças e Problemas Relacionados Ă SaĂșde. Foram verificadas 59 espĂ©cies com propriedades medicinais distribuĂdas em 36 famĂlias botĂąnicas, com o predomĂnio da famĂlia Lamiaceae. Enfermidades de afecçÔes digestivas foram as mais indicadas. O chĂĄ foi o preparado de maior frequĂȘncia
Classification of Osteogenesis Imperfecta revisited
In 1979 Sillence proposed a classification of Osteogenesis Imperfecta (OI) in OI types I, II, III and IV. In 2004 and 2007 this classification was expanded with OI types V-VIII because of distinct clinical features and/or different causative gene mutations. We propose a revised classification of OI with exclusion of OI type VII and VIII since these types have been added because of genetic criteria (autosomal recessive inheritance) while the clinical and radiological features are indistinguishable from OI types II-IV. Instead, we propose continued use of the Sillence criteria I, II-A, II-B, II-C, III and IV for clinical and radiological classification of OI with additional mentioning of the causative mutated gene to this classification. OI type V and VI are still part of this revised classification, because of the distinguishing clinical/radiological and/or histological features observed in these types. (C) 2009 Elsevier Masson SAS. All rights reserve
Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin Topoisomerase I (top1) inhibitors
In search for a novel chemotype to develop topoisomerase I (Top1) inhibitors, the pyrazolo[1,5-a]quinazoline nucleus, structurally related to the indenoisoquinoline system precursor of well-known Top1 poisons, was variously decorated (i.e., a substituted phenyl ring at 2- or 3-position, a protonable side chain at 4- or 5-position), affording a number of Top1 inhibitors with cleavage patterns common to CPT and MJ-III-65. SARs data were rationalized by means of an advanced docking protocol. © 2013 American Chemical Society